Module 6: Treatment of Candidemia/Invasive Candidiasis and Candiduria
This learning activity has been designated to a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.
After completing this educational activity, the learner should be better able to:
- Apply the guidelines of the Infectious Diseases Society of America for the treatment of candidemia and acute hematogenously disseminated candidiasis.
Describe the differing treatment options for stable and unstable moderately severe–to-severely ill patients as well as for patients infected with Candida glabrata and Candida krusei.
Discuss the value of fluconazole, caspofungin, anidulafungin, micafungin, and amphotericin B compounds in the treatment of candidemia/invasive candidiasis and potential problems for the echinocandins in treating Candida parapsilosis infections.
Explain that asymptomatic candiduria is not treated while Candida cystitis and pyleonephritis require systemic antifungal agents.
This learning activity is intended for oncologists, hematologists, infectious disease specialists who treat transplant patients and other patient populations at risk for developing fungal infections.
Release Date: January 19, 2009
Expiration date: January 19, 2010
(*Please check this box to proceed - required)
Start the Module